Research Papers:

The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis

BaSang CiRen, Xinhua Wang and Ziwen Long _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81493-81511. https://doi.org/10.18632/oncotarget.13277

Metrics: PDF 4697 views  |   HTML 2982 views  |   ?  


BaSang CiRen1, Xinhua Wang2, Ziwen Long3

1Department of Medicine, Shigatse People’s Hospital, Shigatse, Tibet, 85700, China

2Department of Dermatology, Shigatse People’s Hospital, Shigatse, Tibet, 85700, China

3Department of Gastric Cancer and Soft-Tissue Sarcoma Sugery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

Correspondence to:

Ziwen Long, email: [email protected]

Keywords: melanoma, chemotherapy, immunotherapy, network meta-analysis

Received: August 10, 2016     Accepted: October 17, 2016     Published: November 10, 2016


Background: Melanoma is a highly malignant tumor that develops from a neural crest derivative called melanocytes. Chemotherapy is recommended for patients with stage III/IV melanoma. Immunomodulation has also been shown to effectively improve the survival rate of such patients. In the current study, we aimed to perform a network meta-analysis on the therapeutic value of chemotherapy and immunotherapy on melanoma.

Results: Twenty randomized controlled trials (RCTs) were enrolled in the study. Our Results indicated that ipilimumab + nivolumab had the highest response rate among all therapies, pembrolizumab also had a good efficacy with an excellent tolerance. Chemotherapy had a low response rate, high adverse effects and progressive diseases qualities, therefore it is not recommended as a preferred treatment for patients with advanced melanoma.

Methods: The Cochrane library, PubMed and Embase databases were searched for relevant articles. Results of the pair-wise meta-analysis were illustrated by odd ratios (ORs) and corresponding 95% confidence intervals (CIs). Network meta-analysis was performed using a random-effects model under Bayesian framework. Results were illustrated by cumulative ORs and corresponding 95% credible interval (CrIs). The probabilities and outcomes of each treatment were ranked and summarized using the surface under the cumulative ranking curve (SUCRA).

Conclusions: We recommend pembrolizumab as the preferred treatment due to its high efficacy and low adverse effects, combination of ipilimumab and nivolumab could be used in severe symptoms.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13277